Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Akash Kulgod noted that because baseline cancer prevalence in healthy populations is under 1%, even tests with 90% or 99% accuracy create massive false positives. Dognosis solves this statistical trap by using breath as an initial sensitive triage, followed by imaging to confirm true structural abnormalities.

Related Insights

While more data seems better, comprehensive imaging scans can be problematic. Each measurement carries a false positive risk, so the cumulative probability of receiving a disruptive, incorrect result becomes material, leading to unnecessary stress and follow-up procedures.

Contrary to hype, AI's most practical current use isn't making complex diagnoses. It's scanning and filtering out the vast number of normal pathology slides. This frees up the limited supply of human pathologists to focus only on abnormal cases, drastically reducing workload and speeding up results.

Akash Kulgod pointed out that analytical chemistry standards like GCMS detect volatile compounds at parts per million, whereas canine olfactory bulbs detect parts per trillion. This sensitivity difference allows dogs to spot stage 1 and 2 cancers easily while ignoring external confounds like recent smoking or specific diets.

Dr. Deb Schrag suggests the main challenge for new molecular cancer screening technologies is not invention, but implementation. The critical task will be deploying these tools at a population scale and effectively managing the logistical challenge of distinguishing true positives from false alarms.

Positioning non-invasive tests to complement rather than replace gold-standard invasive procedures accelerates clinical integration. By filtering out low-risk cases, liquid biopsies eliminate diagnostic bottlenecks and expedite invasive interventions for patients with verified molecular signatures of malignancy.

Testing for hundreds of biomarkers is not inherently better and can be harmful. With a ~95% accuracy rate per test, running more tests increases the odds of a false positive. This leads to chasing down non-existent issues with doctors, initiating diagnostic processes that carry their own risks.

Even a highly specific liquid biopsy test will produce many false positives in the general population. This is a mathematical certainty dictated by Bayes' theorem: when the 'prior probability' (the base rate of cancer) is very low, most positive signals will be statistical noise, not actual disease.

Individual early-detection tests like blood biopsies or MRIs are imperfect, leading to false positives and negatives. The next step in diagnostics is a "multimodal" approach, layering different screening types, such as genomic blood tests and imaging, to create a more accurate and comprehensive picture of a patient's health.

Instead of competing with advanced technologies like liquid biopsies or standard care, this breath test is positioned as a complementary first step. It serves as a valuable "enrichment layer" and risk stratification tool, which increases the prevalence of cancer in the group receiving downstream diagnostics, thereby making those subsequent tests more effective and cost-efficient.

The test's primary purpose is not to replace definitive diagnostics like mammograms but to act as a scalable, low-cost pre-screening tool. In low-resource settings, it can stratify a large population, identifying a high-risk group that can then be targeted with more expensive and resource-intensive screening methods, improving efficiency.

Stack orthogonal tests to fix Bayes law screening false positives | RiffOn